Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants With Advanced Malignancies Previously Enrolled in Studies of Pemigatinib

Next Previous
Trial Profile

An Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants With Advanced Malignancies Previously Enrolled in Studies of Pemigatinib

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 25 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pemigatinib (Primary) ; Pembrolizumab; Retifanlimab
  • Indications Cancer
  • Focus Adverse reactions
  • Sponsors Incyte Corporation

Most Recent Events

  • 17 Apr 2024 Status changed from active, no longer recruiting to discontinued pertaining to a business decision seeing the availability of commercial drug and other options for accessing study drug treatment.
  • 12 Jan 2024 Planned End Date changed from 29 Dec 2023 to 29 Mar 2024.
  • 12 Jan 2024 Planned primary completion date changed from 29 Dec 2023 to 29 Mar 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top